Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Invivyd Inc. (IVVD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: IVVD (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 75.8% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 71.98M USD | Price to earnings Ratio - | 1Y Target Price 6.6 |
Price to earnings Ratio - | 1Y Target Price 6.6 | ||
Volume (30-day avg) 4665913 | Beta 0.09 | 52 Weeks Range 0.35 - 4.74 | Updated Date 03/30/2025 |
52 Weeks Range 0.35 - 4.74 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.43 |
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.1 | Actual -0.15 |
Profitability
Profit Margin - | Operating Margin (TTM) -139.14% |
Management Effectiveness
Return on Assets (TTM) -61.64% | Return on Equity (TTM) -138.71% |
Valuation
Trailing PE - | Forward PE 4.29 | Enterprise Value 3931867 | Price to Sales(TTM) 2.84 |
Enterprise Value 3931867 | Price to Sales(TTM) 2.84 | ||
Enterprise Value to Revenue 0.15 | Enterprise Value to EBITDA 0.78 | Shares Outstanding 119961000 | Shares Floating 47996574 |
Shares Outstanding 119961000 | Shares Floating 47996574 | ||
Percent Insiders 18.09 | Percent Institutions 71.3 |
Analyst Ratings
Rating 4 | Target Price 5.89 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Invivyd Inc.
Company Overview
History and Background
Invivyd Inc., formerly Adagio Therapeutics, is a biopharmaceutical company focused on developing and commercializing antibody-based therapies for infectious diseases. It was founded in 2020 with a focus on COVID-19, but has since evolved its strategy.
Core Business Areas
- Antibody Development: Discovery and development of monoclonal antibodies to treat and prevent serious viral infections.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their antibody candidates.
- Commercialization: Preparing for the potential commercial launch of their products, subject to regulatory approval.
Leadership and Structure
Invivyd Inc. is led by a team of experienced executives in the biopharmaceutical industry. The organizational structure typically includes departments for research and development, clinical operations, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- Vixivremab (INV2131): A broadly neutralizing monoclonal antibody designed to target conserved regions of the SARS-CoV-2 virus, aiming to address current and future variants. Currently in clinical development. Competitors include companies developing broad-spectrum antivirals and pan-coronavirus vaccines.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Demand for effective treatments for infectious diseases remains strong, especially with the emergence of new variants.
Positioning
Invivyd Inc. is positioned as a company developing novel antibody therapies for viral infections. Its competitive advantage lies in its approach to target conserved regions of viruses and develop broadly neutralizing antibodies.
Total Addressable Market (TAM)
The TAM for broadly neutralizing antibodies against viral infections is substantial, potentially reaching billions of dollars annually. Invivyd Inc. is positioned to capture a portion of this TAM through the development and commercialization of its antibody candidates.
Upturn SWOT Analysis
Strengths
- Proprietary antibody platform
- Experienced management team
- Focus on broadly neutralizing antibodies
- Potential to address unmet needs in infectious disease treatment
Weaknesses
- Limited product pipeline
- Reliance on clinical trial success
- High cash burn rate
- Dependence on regulatory approvals
Opportunities
- Expansion of antibody platform to other viral infections
- Partnerships and collaborations
- Government funding and grants
- Potential for breakthrough therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in the competitive landscape
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- Regeneron Pharmaceuticals (REGN)
- Vir Biotechnology (VIR)
Competitive Landscape
Invivyd Inc. faces competition from larger, more established pharmaceutical companies with broader portfolios and greater resources. Its competitive advantage lies in its novel antibody platform.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth reflects the company's transition from a COVID-19 focused company to a broader infectious disease focus.
Future Projections: Future growth depends on the successful development and commercialization of their antibody candidates and estimated from analyst estimates
Recent Initiatives: Focus on Vixivremab (INV2131) development and clinical trials.
Summary
Invivyd Inc. is a development-stage biopharmaceutical company with a focus on antibody-based therapies for infectious diseases. Its success hinges on the clinical development and commercialization of its lead candidate, Vixivremab. The company faces significant competition and financial risks but also has the potential to address unmet needs in infectious disease treatment with strong research and development programs. Investors need to be aware of the high risk as it is a pre-revenue company.
Similar Companies
- GILD
- REGN
- VIR
- LLY
- ABBV
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- News articles
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Invivyd Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-08-06 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 99 | Website https://invivyd.com |
Full time employees 99 | Website https://invivyd.com | ||
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. It developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. The company's pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrevimab, that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.